{"entity":{"id":"nct05687266","kind":"trial","name":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","aka":["AVANZAR"],"tldr":"A phase 3 trial of Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations. ClinicalTrials.gov record last updated 2026-04-22: active not recruiting. Enrollment is actual at 1350 participants. Primary completion is estimated at 2027-11-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel. Registered primary measures: Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive population; Overall Survival (OS) in the non-squamous TROP2 biomarker positive population; PFS by BICR in the non-squamous population.","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05687266","url":"https://clinicaltrials.gov/study/NCT05687266"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["adc","checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["datopotamab-deruxtecan","durvalumab","carboplatin","pembrolizumab","cisplatin","pemetrexed"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-04-22: active not recruiting. Enrollment is actual at 1350 participants. Primary completion is estimated at 2027-11-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT05687266","phase":"3","setting":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","sponsor":"AstraZeneca","participation":[{"nct":"NCT05687266","source":"https://clinicaltrials.gov/study/NCT05687266","fetchedAt":"2026-10-07T16:53:49.617Z","studySha256":"5c6a9eb2072d141755726b6d5155c2b1c72ffe57fe422616c397a58fe4c99208","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-04-22","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1350,"enrolmentType":"ACTUAL","siteCount":254,"recruitingSiteCount":0,"countries":["Austria","Brazil","Bulgaria","Canada","China","France","Germany","Greece","Hungary","India","Italy","Japan","Mexico","Peru","Poland","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom","United States","Vietnam"]}],"started":"2022-12-29","startedType":"actual","enrolled":1350,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05687266/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}